Physician profile
Simpson B Tanner
NPI 1346332756
$53,346.35
in general payments reported to CMS, 2019-2025
9 companies · $6,583 in 2025
The $6,583 reported for 2025 was more than what 88% of Rheumatology providers received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $20K · 2020: $6,555 · 2021: $15K · 2022: $5,370 · 2024: $61.76 · 2025: $6,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $5,483 · Travel and Lodging: $874 · Food and Beverage: $289.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $5,482.50 |
| Travel and Lodging | $873.71 |
| Food and Beverage | $289.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $25,562.51 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $10,800.00 | 2021 | |
| Kyowa Kirin, INC. | $6,517.64 | 2025 | |
| Csl Behring | $4,190.00 | 2020-2022 | |
| Genzyme Corporation | $2,715.82 | 2019-2021 | |
| Amgen INC. | $2,565.84 | 2022-2025 | Evenity |
| Radius Health, INC. | $961.76 | 2021-2024 | Tymlos |
| Circassia INC. | $18.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Simpson Tanner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.